Seattle Genetics to buy Cascadian Therapeutics for $614m
Seattle Genetics has agreed to acquire Cascadian Therapeutics, a clinical-stage biopharmaceutical company engaged in the development of product candidates for the treatment of cancer, for around $614m.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.